Kewaunee Scientific Sales Rise 17.3% to $282M, Debt Cut by $20M
KEQU•Kewaunee Scientific reported fiscal 2026 sales of $282.0 million, up 17.3% year-over-year, with EBITDA of $22.4 million and net earnings of $9.6 million as diluted EPS declined to $3.22. The company integrated Nu Aire into its Lab Products Group, boosted international sales 9.9%, and reduced long-term debt by $20 million.
1. Fiscal Year 2026 Financial Highlights
Kewaunee reported fiscal 2026 sales of $281.999 million, a 17.3% increase from $240.472 million a year earlier. Pre-tax earnings were $13.733 million, net earnings were $9.618 million, and diluted EPS stood at $3.22 versus $3.83; annual EBITDA rose to $22.425 million from $21.613 million.
2. Segment Performance
The Lab Products Group delivered $214.886 million in sales, up 19.8%, with segment net earnings of $14.156 million and EBITDA of $25.059 million despite construction headwinds and tariff pressures. International segment sales increased 9.9% to $67.113 million, generating net earnings of $4.023 million and EBITDA of $5.933 million amid geopolitical uncertainty.
3. Balance Sheet and Backlog
Long-term debt declined by approximately $20 million to $40.851 million, improving the debt-to-equity ratio to 0.61. Cash on hand was $11.617 million, working capital was $57.046 million, and the total order backlog reached $165.9 million, including $118.8 million in the Lab Products Group and $47.1 million internationally.
